StreetInsider.com News Articles

Arrowhead Pharma (ARWR) PT Raised to $109 at UBS

Thu, 15 Oct 2026 09:12:54 -0400

UBS analyst Joon Lee raised the price target on Arrowhead Pharma (NASDAQ: ARWR) to $109.00 (from $63.00) while maintaining a Buy rating.

Arrowhead Pharma (ARWR) Reiterated at Overweight by Cantor Fitzgerald on ARO-MAPT Ph1 Data

Thu, 15 Oct 2026 07:57:34 -0400

Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Arrowhead Pharma (NASDAQ: ARWR).

The analyst commented, "ARWR reported positive Phase 1 data for ARO-MAPT in healthy volunteers. ARWR also hosted a webinar today (10/14) to discuss the data in detail. 70-75% reduction in CSF tau with ARO-MAPT in healthy volunteers is better than the 50-60% reduction shown preclinically and exceeds what many investors were expecting. Durability also looks good, with at least quarterly dosing likely. Overall, these data are validating for the CNS platform. Two key differentiators for ARO-MAPT are subcutaneous delivery and consistent knockdown in deep brain regions,

H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR)

Thu, 15 Oct 2026 06:59:09 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $120.00 price target on Arrowhead Pharma (NASDAQ: ARWR).

The analyst commented: 'On October 14, Arrowhead hosted a webinar to review interim healthy-volunteer results announced earlier that day from the ongoing placebo-controlled Phase 1/2a trial evaluating ARO-MAPT, a subcutaneous RNA interference (RNAi) therapeutic targeting the microtubule-associated protein tau (MAPT) gene in the brain and reduce tau production (links to webinar and deck). Joining the discussion were President and CEO Christopher Anzalone, Chief Medical Officer and Head of R&D James Hamilton, Senior Vice President, Finance and Investor Relations Vince Anzalone, and key opinion

Arrowhead jumps as breakthrough Alzheimer’s drug clears brain barrier

Wed, 14 Oct 2026 08:13:31 -0400

Investing.com -- Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) leaped 6.7% on Wednesday after the biotechnology firm unveiled highly anticipated clinical data that could reshape the landscape of Alzheimer's treatment. In a landmark achievement for RNA therapies, the company's experimental drug ARO-MAPT demonstrated an unprecedented ability to reach the brain and drastically reduce the proteins associated with neurodegeneration.

The interim Phase 1/2a data revealed that ARO-MAPT achieved a staggering 73% average reduction in total tau proteins in the cerebrospinal fluid of healthy volunteers by Day 105, with some individuals seeing drops as high as 85%. This milestone represents

Arrowhead jumps as breakthrough Alzheimer’s drug clears brain barrier

Wed, 14 Oct 2026 08:13:31 -0400

Arrowhead drug cuts tau levels 73% in early trial data

Wed, 14 Oct 2026 07:30:20 -0400

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported interim Phase 1/2a clinical data for ARO-MAPT, its investigational RNA interference (RNAi) therapy targeting tau protein, showing mean cerebrospinal fluid (CSF) total tau reductions of up to 73% in healthy volunteers at Day 105.

ARO-MAPT is designed to silence expression of the microtubule-associated protein tau (MAPT) gene in the central nervous system, reducing production of all six isoforms of the tau protein. The drug is being developed as a potential treatment for Alzheimer's disease and other tauopathies, including MAPT-related frontotemporal dementia and Progressive Supranuclear Palsy.

According to the company's press release, participants receiving ARO-MAPT at 12.8 mg/kg

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

Wed, 14 Oct 2026 07:30:00 -0400

Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injection
ARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on Day 105, with a maximum individual reduction of 85%, supporting the potential for quarterly dosing
Arrowhead will host a webinar today, October 14, at 2:30 PM ET/11:30 am PT to review additional interim results

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company’s investigational RNA interference (RNAi) therapeutic being developed

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

Wed, 14 Oct 2026 07:30:00 -0400

Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injection
ARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on Day 105, with a maximum individual reduction of 85%, supporting the potential for quarterly dosing
Arrowhead will host a webinar today, October 14, at 2:30 PM ET/11:30 am PT to review additional interim results

FDA grants Arrowhead's plozasiran entry into STAR pilot program

Wed, 07 Oct 2026 07:30:48 -0400

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that the U.S. Food and Drug Administration has granted plozasiran entry into the Split Real Time Application Review (STAR) pilot program, in connection with the company's planned supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG).

The FDA STAR pilot program is designed to shorten the time from a complete sNDA submission to the action date for certain supplemental indications of already-approved drugs. To qualify, the FDA must determine that clinical evidence from adequate and well-controlled investigations indicates the drug may demonstrate substantial improvement on a clinically relevant endpoint over available therapies.

Programs accepted into the STAR

FDA grants Arrowhead's plozasiran entry into STAR pilot program

Wed, 07 Oct 2026 07:30:48 -0400

Programs accepted into the STAR

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

Wed, 07 Oct 2026 07:30:00 -0400

- FDA STAR pilot program aims to shorten the time from complete supplement submission to the action date to allow earlier patient access to therapies that address an unmet medical need

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead’s upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis, which is associated

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

Wed, 07 Oct 2026 07:30:00 -0400

- FDA STAR pilot program aims to shorten the time from complete supplement submission to the action date to allow earlier patient access to therapies that address an unmet medical need

Arrowhead Pharmaceuticals to hold ARO-MAPT webinar Oct. 14

Tue, 29 Sep 2026 07:30:40 -0400

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it will host an R&D webinar on October 14, 2026, at 11:30 AM PDT focused on its investigational therapy ARO-MAPT and its central nervous system pipeline.

The webinar will include interim clinical data from the AROMAPT-SC-1001 Phase 1/2a study, a placebo-controlled, dose-escalating trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MAPT in up to 64 healthy volunteers and up to 48 subjects with early Alzheimer's disease.

Adam Boxer, M.D., Ph.D., a professor in the Department of Neurology at the University of California, San Francisco, is scheduled to present alongside Arrowhead management. The approximately 60-minute session will

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Tue, 29 Sep 2026 07:30:00 -0400

– ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain barrier –

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead’s central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Tue, 29 Sep 2026 07:30:00 -0400

– ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain barrier –

Goldman Sachs Assumes Arrowhead Pharma (ARWR) at Neutral

Thu, 24 Sep 2026 05:33:28 -0400

(Updated - September 24, 2026 5:33 AM EDT)

Goldman Sachs analyst Andrea Newkirk assumes coverage on Arrowhead Pharma (NASDAQ: ARWR) with a Neutral rating and a price target of $74.00.

The analyst comments "ARWR is a commercial-stage global biopharmaceutical company leveraging its proprietary Targeted RNAi Molecule (TRiM) platform to develop tissue-specific gene-silencing therapies across cardiometabolic, pulmonary, renal, and neurodegenerative diseases. The company's first commercial product, Redemplo (plozasiran), is approved globally as the first and only siRNA treatment for familial chylomicronemia syndrome (FCS) studied in both clinically and genetically confirmed patients. The primary near-term growth driver is plozasiran's expansion into severe hypertriglyceridemia (sHTG),

Goldman Sachs Assumes Arrowhead Pharma (ARWR) at Neutral

Thu, 24 Sep 2026 05:33:28 -0400

(Updated - September 24, 2026 5:33 AM EDT)

Goldman Sachs analyst Andrea Newkirk assumes coverage on Arrowhead Pharma (NASDAQ: ARWR) with a Neutral rating and a price target of $74.00.

Arrowhead reports early data for dual-gene RNAi therapy ARO-DIMER-PA

Tue, 15 Sep 2026 07:31:16 -0400

Arrowhead Pharmaceuticals (NASDAQ: ARWR) released interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, an investigational RNA interference (RNAi) therapeutic being studied as a potential treatment for atherosclerotic cardiovascular disease due to mixed hyperlipidemia.

ARO-DIMER-PA is designed to silence two genes simultaneously — proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC3) — using a single RNAi molecule. According to the company, it is the first clinical candidate designed to selectively silence two genes with a single RNAi molecule.

In the single-dose portion of the trial, participants with mixed hyperlipidemia showed dose-dependent mean maximal reductions in serum PCSK9 of

Arrowhead reports early data for dual-gene RNAi therapy ARO-DIMER-PA

Tue, 15 Sep 2026 07:31:16 -0400

In the single-dose portion of the trial, participants with mixed hyperlipidemia showed dose-dependent mean maximal reductions in serum PCSK9 of

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Tue, 15 Sep 2026 07:30:00 -0400

- ARO-DIMER-PA achieved deep and durable silencing of two genes with a single RNAi molecule

- Mean maximal single dose reductions in serum PCSK9 of 72% and APOC3 of 88%

- Clinical validation further demonstrates Arrowhead’s position as the leading innovator in siRNA therapies -

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Tue, 15 Sep 2026 07:30:00 -0400

- ARO-DIMER-PA achieved deep and durable silencing of two genes with a single RNAi molecule

- Mean maximal single dose reductions in serum PCSK9 of 72% and APOC3 of 88%

- Clinical validation further demonstrates Arrowhead’s position as the leading innovator in siRNA therapies -

Citi Starts Arrowhead Pharma (ARWR) at Buy

Tue, 08 Sep 2026 01:50:44 -0400

Citi analyst Eric Joseph initiates coverage on Arrowhead Pharma (NASDAQ: ARWR) with a Buy rating and a price target of $108.00.

For an analyst ratings summary and ratings history on Arrowhead Pharma click here. For more ratings news on Arrowhead Pharma click here.

Shares of Arrowhead Pharma closed at $86.34 yesterday.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.